Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 1998

View Archived Issues

British Biotech: Q2 1998 highlights

Orion: 1998 interim report

Cantab: Q3 1998 highlights

Neurobiological Technologies: Q3 1998 highlights

Xenova: nine-month highlights

U.S. patent issues for conantokin-G and derivatives

Shearwater Polymers will pegylate interferon alfa-2a for Roche under new agreement

New study will assess troglitazone in the prevention of IGT

Ligand initiates phase II trial with Targretin capsules for treatment of breast cancer

North American Vaccine continues product launch of Certiva in U.S.

Preliminary results announced for pleconaril pediatric study; other trials in progress

Schwarz drops development of Biostent and cancels agreement with NeoRx

Onyx presents new addition to anticancer arsenal at gene therapy conference

Pharmacopeia achieves milestone in collaboration with Schering-Plough

Study points to improved efficacy with levalbuterol vs. racemic albuterol

Generex receives FDA approval to begin human trials of oral insulin formulation

Zyrtec available in Japan through UCB licensees

Pfizer claims new series for inhibiting PDE4 and TNF production

NOS inhibitors claimed by Astra for use in inflammation and pain

Agents for diabetes and related disorders developed by Dr. Reddy's team

Novel antitumor vinca alkaloids patented by Pierre Fabre

New compounds for immunoinflammatory and neoplastic diseases in the pipeline at Ferring

Pharmacological profile of PNU-99194A, a D3-preferring dopamine antagonist, reviewed

Potential megamerger of Rhone-Poulenc and Hoechst life sciences businesses

Grape polyphenols now shown to have neuroprotective properties

FK-3657: clinical candidate from novel class of nonpeptide BK antagonists

Potent and highly selective CCK-A antagonist designed by Tobishi

Design, synthesis and antiviral activity of A-5021 discussed this week in Kyoto

Human neural stem cells as source of transplantable cells for CNS disorders

Noval antiasthmatic agent from Takeda with dual antiinflammatory and bronchodilating effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...